Literature DB >> 27666939

FX knockout CHO hosts can express desired ratios of fucosylated or afucosylated antibodies with high titers and comparable product quality.

Salina Louie1, Benjamin Haley2, Brett Marshall3, Amy Heidersbach2, Mandy Yim1, Martina Brozynski3, Danming Tang1, Cynthia Lam1, Bronislawa Petryniak4, David Shaw1, Jeongsup Shim3, Aaron Miller3, John B Lowe4, Brad Snedecor1, Shahram Misaghi1.   

Abstract

During antibody dependent cell cytotoxicity (ADCC) the target cells are killed by monocytes and natural killer cells. ADCC is enhanced when the antibody heavy chain's core N-linked glycan lacks the fucose molecule(s). Several strategies have been utilized to generate fully afucosylated antibodies. A commonly used and efficient approach has been knocking out the FUT8 gene of the Chinese hamster ovary (CHO) host cells, which results in expression of antibody molecules with fully afucosylated glycans. However, a major drawback of the FUT8-KO host is the requirement for undertaking two separate cell line development (CLD) efforts in order to obtain both primarily fucosylated and fully afucosylated antibody species for comparative studies in vitro and in vivo. Even more challenging is obtaining primarily fucosylated and FUT8-KO clones with similar enough product quality attributes to ensure that any observed ADCC advantage(s) can be strictly attributed to afucosylation. Here, we report generation and use of a FX knockout (FXKO) CHO host cell line that is capable of expressing antibody molecules with either primarily fucosylated or fully afucosylated glycan profiles with otherwise similar product quality attributes, depending on addition of fucose to the cell culture media. Hence, the FXKO host not only obviates the requirement for undertaking two separate CLD efforts, but it also averts the need for screening many colonies to identify clones with comparable product qualities. Finally, FXKO clones can express antibodies with the desired ratio of primarily fucosylated to afucosylated glycans when fucose is titrated into the production media, to allow achieving intended levels of FcγRIII-binding and ADCC for an antibody. Biotechnol. Bioeng. 2017;114: 632-644.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  GDP-4-keto-6-d-deoxymannose epimerase/GDP-4-keto-6-l-galactose reductase (FX); fucose; fucosylation; fully afucosylated antibody; glycans

Mesh:

Substances:

Year:  2016        PMID: 27666939     DOI: 10.1002/bit.26188

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  11 in total

1.  Glycoengineering of Mammalian Expression Systems on a Cellular Level.

Authors:  Kelley M Heffner; Qiong Wang; Deniz Baycin Hizal; Özge Can; Michael J Betenbaugh
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 2.  Glycoengineering of Antibodies for Modulating Functions.

Authors:  Lai-Xi Wang; Xin Tong; Chao Li; John P Giddens; Tiezheng Li
Journal:  Annu Rev Biochem       Date:  2019-03-27       Impact factor: 23.643

3.  Establishment of serum-free adapted Chinese hamster ovary cells with double knockout of GDP-mannose-4,6-dehydratase and GDP-fucose transporter.

Authors:  Ryo Misaki; Masashi Iwasaki; Hiroki Takechi; Noriko Yamano-Adachi; Takao Ohashi; Hiroyuki Kajiura; Kazuhito Fujiyama
Journal:  Cytotechnology       Date:  2022-01-15       Impact factor: 2.058

Review 4.  Sialylation as an Important Regulator of Antibody Function.

Authors:  Ravi Vattepu; Sunny Lyn Sneed; Robert M Anthony
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

5.  Improving titer while maintaining quality of final formulated drug substance via optimization of CHO cell culture conditions in low-iron chemically defined media.

Authors:  Jianlin Xu; Matthew S Rehmann; Xuankuo Xu; Chao Huang; Jun Tian; Nan-Xin Qian; Zheng Jian Li
Journal:  MAbs       Date:  2018-02-20       Impact factor: 5.857

Review 6.  L-fucose, a sugary regulator of antitumor immunity and immunotherapies.

Authors:  Emma Adhikari; Qian Liu; Chase Burton; Andrea Mockabee-Macias; Daniel K Lester; Eric Lau
Journal:  Mol Carcinog       Date:  2022-02-02       Impact factor: 5.139

7.  Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation.

Authors:  Ying Zhou; Tomohiko Fukuda; Qinglei Hang; Sicong Hou; Tomoya Isaji; Akihiko Kameyama; Jianguo Gu
Journal:  Sci Rep       Date:  2017-09-14       Impact factor: 4.379

Review 8.  The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.

Authors:  Natasha A Pereira; Kah Fai Chan; Pao Chun Lin; Zhiwei Song
Journal:  MAbs       Date:  2018-07       Impact factor: 5.857

Review 9.  Genetic glycoengineering in mammalian cells.

Authors:  Yoshiki Narimatsu; Christian Büll; Yen-Hsi Chen; Hans H Wandall; Zhang Yang; Henrik Clausen
Journal:  J Biol Chem       Date:  2021-02-20       Impact factor: 5.157

10.  Generation of FX-/- and Gmds-/- CHOZN host cell lines for the production of afucosylated therapeutic antibodies.

Authors:  Weiyi Liu; Roshan Padmashali; Omar Quintero Monzon; Dianna Lundberg; Shan Jin; Brian Dwyer; Yun-Jung Lee; Anisha Korde; Sophia Park; Clark Pan; Bohong Zhang
Journal:  Biotechnol Prog       Date:  2020-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.